The United Kingdom and the United States have finalized a important trade agreement that will keep no import taxes on UK drug shipments going into the American market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to raise expenditure on drugs through the National Health Service (NHS). This commitment ensures that import taxes on these key exports will be held at zero for a duration of three years.
This agreement is in response to earlier statements to significantly raise tariffs on branded drug imports, with increases mentioned up to 100%.
"This deal between the Britain strengthens the international landscape for cutting-edge drugs and introduces long-overdue fairness to transatlantic drug exports," a statement said.
Commercial Importance
Medicines represent one of the the United Kingdom's biggest exports to the US, which is easily the biggest buyer for major British pharmaceutical firms.
Statistics reveal that in the one-year period to the end of last September, the UK shipped medicines valued at over eleven billion pounds to the US. This figure accounted for a significant portion of all goods exports in that timeframe.
"This agreement safeguards jobs, increases investment and facilitates the UK to emerge as a international leader for life sciences," a government official stated.
Detailed British Pledges
The deal involves several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to raise overall health service expenditure on treatments from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to control costs will be restricted at 15%. Previously, refunds exceeded twenty percent.
Industry Background
The pact follows a ongoing row between the sector and the ministers over spending levels and approval rates.
This friction were heightened by assertions that US patients were charged a premium for the same drugs than consumers in the other developed nations.
Recently, several major drug company projects in the UK have been delayed or abandoned, while substantial funding commitments have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS needed to spend more on treatments, noting that its spending on drugs had shrunk as a percentage of its total funding over the previous ten-year period.
